Reneo Pharmaceuticals Completes Clinical Study in Primary Mitochondrial Myopathies and Receives FDA Orphan Drug Designation for REN001

Print Friendly, PDF & Email

SECOND ARTICLE: SAN DIEGO, June 23, 2020 /PRNewswire/ — Reneo Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development has granted Orphan Drug Designation to the company’s lead drug candidate, REN001, for the treatment of primary mitochondrial myopathies (PMM). The company also announced positive […]